Spiro Neuromodulation System
Severe Asthma
Key Facts
About Spiro Medical
Spiro Medical is a private, clinical-stage medical device company pioneering neuromodulation for chronic respiratory diseases. The company's core technology, the Spiro Neuromodulation System, aims to treat severe asthma, chronic cough, and COPD by modulating airway nerves, offering a potential alternative to drug-based therapies. Operating in the large and growing respiratory therapeutics market, Spiro Medical is positioned to address significant unmet needs in patient populations poorly served by current standards of care. As a pre-revenue entity, its success hinges on clinical validation, regulatory clearance, and subsequent commercial execution of its lead device.
View full company profileAbout Spiro Medical
Spiro Medical is a private, clinical-stage medical device company pioneering neuromodulation for chronic respiratory diseases. The company's core technology, the Spiro Neuromodulation System, aims to treat severe asthma, chronic cough, and COPD by modulating airway nerves, offering a potential alternative to drug-based therapies. Operating in the large and growing respiratory therapeutics market, Spiro Medical is positioned to address significant unmet needs in patient populations poorly served by current standards of care. As a pre-revenue entity, its success hinges on clinical validation, regulatory clearance, and subsequent commercial execution of its lead device.
View full company profileAbout Spiro Medical
Spiro Medical is a private, clinical-stage medical device company pioneering neuromodulation for chronic respiratory diseases. The company's core technology, the Spiro Neuromodulation System, aims to treat severe asthma, chronic cough, and COPD by modulating airway nerves, offering a potential alternative to drug-based therapies. Operating in the large and growing respiratory therapeutics market, Spiro Medical is positioned to address significant unmet needs in patient populations poorly served by current standards of care. As a pre-revenue entity, its success hinges on clinical validation, regulatory clearance, and subsequent commercial execution of its lead device.
View full company profileTherapeutic Areas
Other Severe Asthma Drugs
| Drug | Company | Phase |
|---|---|---|
| Depemokimab (GSK3511294) | GSK | Phase III |
| Severe Asthma (FFA4 receptor) | Keltic Pharma Therapeutics | Pre-clinical |
| KN-002 | Kinaset Therapeutics | Pre-clinical |
| FB704A | Oneness Biotech | Phase 1 |
| GB-0895 | Generate Biomedicines | Phase 3 |
| Verekitug (UPB-101) | Upstream Bio | Phase 2 |